Statement From The IDF Related To Studies Published In Diabetelogia Suggesting Possible Link Between Insulin Glargine And Cancer

Main Category: Diabetes
Also Included In: Cancer / Oncology
Article Date: 30 Jun 2009 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The International Diabetes Federation (IDF) called for urgent assessment and responses from regulatory authorities into a possible link between the use of insulin glargine (an insulin analogue) and increased risk of cancer based on findings published on 26 June, 2009 in Diabetelogia, the journal of the European Association for the Study of Diabetes (EASD).

The online data published in Diabetelogia is based on four studies relating to a possible link between a long-acting insulin analogue, insulin glargine and cancer. According to EASD, the findings are based on evidence from studies in Germany, Sweden, Scotland and the United Kingdom. The studies however, are not conclusive.

The International Diabetes Federation understands the concern about the Diabetelogia study findings but urges the diabetes community to wait for the current scientific information to be released and calls for urgent further scientific studies to be undertaken in other countries.

The International Diabetes Federation stresses that it is important that people needing insulin do not stop taking the drug. IDF cautioned that people with diabetes should see their doctor for advice before considering any change to their treatment.

Source
International Diabetes Federation